MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    A pilot study on the shift from rasagiline to safinamide in fluctuating Parkinson’s disease patients

    M.S Sforza, F.E Pontieri, D.R Rinaldi, E.B Bianchini (Rome, Italy)

    Objective: Here we investigated the consequences of the shift from rasagiline (RS) to SF in fluctuating PD patients. To this end, we selected patients from…
  • MDS Virtual Congress 2020

    A monocentric experience of Apomorphine pump follow-up on PD patients: The Optipump Cohort

    C. Virbel-Fleischman, M. Houot, Y. Rétory, S. Hardy, J.C Corvol, D. Grabli (Gentilly, France)

    Objective: The goal of this study is to describe the factors that may have an impact on Continuous Subcutaneous Apomorphine Infusion (CSAI) therapy initiation and…
  • MDS Virtual Congress 2020

    Towards a scoring system to distinguish early parkinsonian variant of multiple system atrophy from Parkinson’s disease

    P. Millar Vernetti, J.A Palma, L. Norcliffe-Kaufmann, M. Pérez, A. Fanciulli, F. Krismer, W. Singer, P. Low, M.T Pellecchia, H.J Kim, C. Shibao, A. Peltier, I. Biaggioni, M.J Martí, C. Terroba-Chambi, M. Merello, D. Goldstein, R. Freeman, C. Gibbons, S. Vernino, G. Wenning, H. Kaufmann (New York, NY, USA)

    Objective: To develop a clinical score to distinguish between the parkinsonian variant of multiple system atrophy (MSA-P) and Parkinson’s disease (PD). Background: The differential diagnosis…
  • MDS Virtual Congress 2020

    Is brain perfusion a differentiating factor between Parkinson’s Disease (PD) and Progressive Supranuclear Palsy – Parkinsonism Predominant (PSP-P)?

    P. Alster, D. Koziorowski, L. Królicki, A. Friedman (Warsaw, Poland)

    Objective: Parkinson’s Disease – Postural Instability Gait Disorder (PD-PIGD) and Progressive Supranuclear Palsy – Parkinsonism Predominant (PSP-P) are entities affected by difficulties in differentiation in…
  • MDS Virtual Congress 2020

    Chromogranin B in cerebrospinal fluid as a novel biomarker for Progressive supranuclear palsy

    H. Takigawa, R. Sakata, T. Inoue-Nishida, H. Kowa, K. Namashima, R. Hanajima (Yonago, Japan)

    Objective: To identify the biomarker associated with progressive supranuclear palsy (PSP) for better understanding of a pathophysiology and clinical diagnosis. Background: PSP is one of…
  • MDS Virtual Congress 2020

    Clinical and nuclear neuroimaging features of Parkinson’s disease with dysphagia

    K. Ohta, T. Nakajima (Kashiwazaki city Niigata, Japan)

    Objective: The clinical and neuroimaging factors associated with dysphagia were investigated in this retrospective data of Parkinson's disease (PD) patients. Background: PD can cause dysphagia…
  • MDS Virtual Congress 2020

    Management practices and long-term follow up of pediatric functional (psychogenic) movement disorder at a tertiary care center

    M. Hull, J.M Maldonado-Duran, M. Parnes (Houston, TX, USA)

    Objective: We evaluated management practices and compared efficacy of specific interventions on remission of symptoms of functional movement disorder (FMD) in our pediatric population. Background: Current recommendations of managing FMD revolve…
  • MDS Virtual Congress 2020

    Effects of Different Side-of-onset on Symptoms, Progression, and Prognosis in Parkinson’s Disease

    X. Huang, Y. Huang, C. Liu, X. Huang, Y. Zhang, Q. Ye (Fuzhou, China)

    Objective: We conducted an ambispective cohort study, with the largest number of involved patients for now, to assess whether the different side-of-onset could affect the…
  • MDS Virtual Congress 2020

    The Feasibility of Using of the Non-Medication in the Treatment of Post-Stroke Vascular Parkinsonism

    O. Tondiy, O. Zavalna (Kharkiv, Ukraine)

    Objective: Vascular parkinsonism is an infrequent but unpleasant complication of cerebrovascular disease, in particular brain stroke. Background: The effect of the complex treatment with non-medication…
  • « Previous Page
  • 1
  • …
  • 147
  • 148
  • 149

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley